Synthesis of a C‐Iminoribofuranoside Analog of the Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitor FK866
Copyright policy )Synthesis of a C‐Iminoribofuranoside Analog of the Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitor FK866
AbstractFK866 (also named APO866 or WK175) is a potent NAMPT inhibitor being evaluated (Phase II) as a potential anticancer drug. The preparation of the C‐iminoribofuranoside analog (2E)‐N‐[4‐(1‐benzoylpiperidin‐4‐yl)butyl]‐3‐{3‐[(2S,3S,4R,5R)‐3,4‐dihydroxy‐5‐(hydroxymethyl)pyrrolidin‐2‐yl]phenyl}prop‐2‐enamide ((−)‐1) is reported.
- École Polytechnique Fédérale de Lausanne EPFL Switzerland
Target, Nicotinamide phosphoribosyltransferase, Inhibitors, Hematologic Malignancies, Pyridine-Nucleotides, Nad Biosynthesis Inhibitor, Visfatin, C-imino-, Human Leukemia-Cells, Colorectal-Cancer, Chs 828, Fk866, In-Vitro, Ribofuranoside analogs, Potent Antitumor-Activity
Target, Nicotinamide phosphoribosyltransferase, Inhibitors, Hematologic Malignancies, Pyridine-Nucleotides, Nad Biosynthesis Inhibitor, Visfatin, C-imino-, Human Leukemia-Cells, Colorectal-Cancer, Chs 828, Fk866, In-Vitro, Ribofuranoside analogs, Potent Antitumor-Activity
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!